Results 11 to 20 of about 24,853 (244)

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis

eJHaem
Bone marrow fibrosis (BMF) is a pathological feature of myelofibrosis, with higher grades associated with poor prognosis. Limited data exist on the association between outcomes and BMF changes.
Stephen T. Oh, Srdan Verstovsek, Vikas Gupta, Uwe Platzbecker, Timothy Devos, Jean‐Jacques Kiladjian, Donal P. McLornan, Andrew Perkins, Maria Laura Fox, Mary Frances McMullin, Adam J. Mead, Miklos Egyed, Jiri Mayer, Tomasz Sacha, Jun Kawashima, Mei Huang, Bryan Strouse, Ruben Mesa   +17 more
doaj   +2 more sources

Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.

New England Journal of Medicine, 2021
BACKGROUND Chronic graft-versus-host disease (GVHD), a major complication of allogeneic stem-cell transplantation, becomes glucocorticoid-refractory or glucocorticoid-dependent in approximately 50% of patients. Robust data from phase 3 randomized studies
R. Zeiser, N. Polverelli, R. Ram, S. Hashmi, R. Chakraverty, J. Middeke, M. Musso, S. Giebel, A. Uzay, P. Langmuir, N. Hollaender, M. Gowda, T. Stefanelli, Stephanie J. Lee, T. Teshima, F. Locatelli   +15 more
semanticscholar   +1 more source

Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis.

Cancer Discovery, 2023
Immune-checkpoint-inhibitor (ICI)-associated myotoxicity involves the heart (myocarditis) and skeletal muscles (myositis), which frequently occur concurrently and is highly fatal.
J. Salem, M. Bretagne, B. Abbar, S. Leonard-Louis, S. Ederhy, alban redheuil, S. Boussouar, L. Nguyen, A. Procureur, Frederic Stein, C. Fenioux, Perrine Devos, P. Gougis, M. Dres, A. Demoule, D. Psimaras, T. Lenglet, T. Maisonobe, M. Pineton de Chambrun, G. Hékimian, C. Straus, J. Gonzalez-Bermejo, D. Klatzmann, A. Rigolet, P. Guillaume-Jugnot, N. Champtiaux, O. Benveniste, N. Weiss, S. Saheb, P. Rouvier, I. Plu, E. Gandjbakhch, M. Kerneis, N. Hammoudi, N. Zahr, C. Llontop, C. Morélot-Panzini, L. Lehmann, Juan Qin, J. Moslehi, M. Rosenzwajg, T. Similowski, Y. Allenbach   +42 more
semanticscholar   +1 more source

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Journal of Clinical Oncology, 2023
PURPOSE Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV, ruxolitinib controls blood counts and improves symptoms.
C. Harrison, J. Nangalia, R. Boucher, Aimee E Jackson, C. Yap, J. O'Sullivan, Sonia Fox, Isaak Ailts, A. Dueck, H. Geyer, Ruben A. Mesa, W. Dunn, Eugene Nadezhdin, N. Curto-Garcia, A. Green, B. Wilkins, J. Coppell, J. Laurie, M. Garg, J. Ewing, S. Knapper, Josephine Crowe, Frederick Chen, I. Koutsavlis, A. Godfrey, S. Arami, M. Drummond, J. Byrne, F. Clark, Carolyn Mead-Harvey, E. J. Baxter, M. McMullin, A. Mead   +32 more
semanticscholar   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source

Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation

Frontiers in Pharmacology, 2022
Bronchiolitis obliterans syndrome (BOS) is a life-threatening pulmonary complication of chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). In this study, we retrospectively identified seven patients
Xiaoyu Zhang, Xiaoli Zhao, Yuyan Shen, Yuanyuan Shi, Lining Zhang, Mengze Hao, Fei Zhao, Rongli Zhang, Jialin Wei, Sizhou Feng, Yi He, Erlie Jiang, Mingzhe Han   +12 more
doaj   +1 more source

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.

New England Journal of Medicine, 2020
BACKGROUND Acute graft-versus-host disease (GVHD) remains a major limitation of allogeneic stem-cell transplantation; not all patients have a response to standard glucocorticoid treatment.
R. Zeiser, N. von Bubnoff, J. Butler, M. Mohty, D. Niederwieser, R. Or, J. Szer, E. Wagner, T. Zuckerman, Bruyère Mahuzier, Judith Xu, C. Wilke, K. Gandhi, G. Socié   +13 more
semanticscholar   +1 more source

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Haematologica, 2015
In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall survival benefit relative to placebo ...
Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W.N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Azra Raza, Kris Vaddi, William Sun, Wei Peng, Victor Sandor, Hagop Kantarjian   +21 more
doaj   +1 more source

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor

Frontiers in Endocrinology, 2023
Weight gain is a known adverse effect of ruxolitinib, a JAK1/2 inhibitor that is the mainstay of treatment for many patients with myelofibrosis. The mechanisms behind weight increase with ruxolitinib is incompletely understood, although decreased adipose
Douglas Tremblay, Mikaela Dougherty, John Mascarenhas, Emily Jane Gallagher   +3 more
doaj   +1 more source

Recent progress of JAK inhibitors for hematological disorders

Immunological Medicine, 2023
JAK inhibitors are important therapeutic options for hematological disorders, especially myeloproliferative neoplasms. Ruxolitinib, the first JAK inhibitor approved for clinical use, improves splenomegaly and ameliorates constitutional symptoms in both ...
Keita Kirito
doaj   +1 more source